Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
Summary of findings table ‐ Adjunctive therapies in addition to… showed no clear difference in adverse events compared with land‐based exercise therapy (low certainty).
Summary of findings table ‐ Adjunctive therapies in addition to… showed no clear difference in adverse events compared with placebo adjunctive therapies (low certainty).
Summary of findings table ‐ More time showed no clear difference in serious adverse events/death compared with less time (low certainty).
Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin detemir (low certainty).
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with other antibiotics (very low certainty).
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
The review found no eligible studies for this question.
Summary of findings: ultrasound‐guided injection of corticosteroid… showed no clear difference in adverse events compared with non‐ultrasound‐guided injection of corticosteroid and local… (low certainty).
It is very uncertain whether summary of findings table ‐ Baclofen changes dropouts due to adverse events compared with acamprosate (very low certainty).
Summary of findings table ‐ Baclofen showed no clear difference in dropouts due to adverse events compared with placebo (high certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in total adverse events compared with onabotulinumtoxinA 20U (moderate certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher major adverse events compared with placebo (moderate certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).